Carmell Therapeutics Announces the Appointment of Sebastian “Sebby” Borriello to Chief Business Officer
PITTSBURGH--(BUSINESS WIRE)--Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Sebastian “Sebby” Borriello joined the company as Chief Business Officer. Carmell Therapeutics has a unique biologic solution that addresses unmet needs in bone and soft tissue treatment and utilizes an innovative, proprietary platform that accelerates and enhances healing, reduces complications, and enables patients to get back to their daily lives more quickly.
“Sebby has a long track record of success with a distinguished record of results in key leadership positions across the pharmaceutical and medical device industries and will be instrumental in the success of Carmell™’s growth,” said Randy Hubbell, President, and Chief Executive Officer.
Mr. Borriello brings 30+ years of experience to Carmell with deep experience developing strategic plans and commercialization in both the pharmaceutical and medical device arena. Twenty-five of those years were with J&J in commercial leadership positions across wound management, biosurgery and aesthetics franchises. He has also had leadership positions at biotech firms and most recently as Chief Commercial Officer at SK Life Science Inc, leading the build out of the commercial organization and growing the SK Life Science Inc organization to become a fully integrated pharmaceutical company. Sebby led the successful US launch of the company’s first product, XCOPRI®, in May 2020. Sebby also played a supportive role in one of the largest biotech IPOs in South Korea ($880 million raise) during the summer of 2020.
"I am proud and excited to join the talented team at Carmell,” said Mr. Borriello. “Biologic development of plasma-based material is an important area that could make a significant impact in a variety of therapeutics areas such as bone and wound healing as well as some aesthetic applications.”
About Carmell Therapeutics
Carmell Therapeutics (Carmell™) is a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based Bioactive Material (“PBM”). PBM is a proprietary formulation of multiple Growth Factors (“GFs”) and other regenerative factors contained in allogeneic platelet-enriched plasma designed to accelerate and enhance healing in bone, skin, and other tissues, as well as stimulate hair regrowth and collagen production after severe injury, disease or aging. The platform technology of PBM is initially targeted to accelerate and enhance healing in bone applications (orthobiologics), Carmell™ believes PBM has the ability to deliver many regenerative factors in spaces like aesthetic medicine (androgenic alopecia), wound care and dental bone substitute. Carmell™ currently has two PBM product candidates in development – a Bone Healing Accelerant (“BHA”) and a Tissue Healing Accelerant (“THA”). BHA has been granted Fast Track designation by the FDA and clinical development is ongoing.
For more information, please visit www.carmellrx.com and engage with us on LinkedIn https://www.linkedin.com/company/carmell-therapeutics